Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruzzese

Showing results (711-720 of 766) with videos related to

Pageof 77
Sort By:
Cancer Cytopathology|December 11, 2019
Evaluation of BRAF, RAS, RET/PTC, and PAX8/PPARg alterations in different Bethesda diagnostic categories: A multicentric prospective study on the validity of the 7-gene panel test in 1172 thyroid FNAs deriving from different hospitals in South ItalyClaudio Bellevicine, Ilaria Migliatico, Roberta Sgariglia, et al.
Archives of Disease in Childhood|January 14, 2019
Complications and risk factors for severe outcome in children with measlesAndrea Lo Vecchio, Andrzej Krzysztofiak, Carlotta Montagnani, et al.
Leukemia Research|June 3, 2026
Association of hypomethylating agents + venetoclax in the real-life treatment of Myeloproliferative Neoplasms in blastic phaseRoberto Latagliata, Novella Pugliese, Dorela Lame, et al.
Annals of Hematology|January 11, 2026
Hypomethylating agents alone or in combination with venetoclax in very elderly acute myeloid leukemia patients: less treatment, better care?Francesco Tarantini, Corinne Contento, Ernesto Vigna, et al.
Hematological Oncology|May 31, 2022
Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trialsEnrica Antonia Martino, Concetta Conticello, Elena Zamagni, et al.
Clinical Rheumatology|July 7, 2022
Apremilast retention rate in clinical practice: observations from an Italian multi-center studyAlarico Ariani, Simone Parisi, Patrizia Del Medico, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|November 3, 2022
Booster dose of SARS-CoV-2 messenger RNA vaccines strengthens the specific immune response of patients with rheumatoid arthritis: A prospective multicenter longitudinal studyChiara Farroni, Alessandra Aiello, Andrea Picchianti-Diamanti, et al.
Current Oncology (Toronto, Ont.)|February 26, 2026
BLOSSOM Dietary Habits and 1-Year Intravesical Recurrence in High-Risk Non-Muscle-Invasive Bladder Cancer Treated with BCGCarlo Buonerba, Raffaele Baio, Felice Crocetto, et al.
Cancer Discovery|April 19, 2026
TNG961 is a selective oral HBS1L molecular glue degrader for the treatment of FOCAD-deleted cancersHilary E Nicholson, Douglas A Whittington, Frank J Bruzzese, et al.
Molecular Cell|February 5, 2010
Substrate-assisted inhibition of ubiquitin-like protein-activating enzymes: the NEDD8 E1 inhibitor MLN4924 forms a NEDD8-AMP mimetic in situJames E Brownell, Michael D Sintchak, James M Gavin, et al.
Pageof 77

Showing results (711-720 of 766) with videos related to

Sort By:
Pageof 77
Cancer Cytopathology|December 11, 2019
Evaluation of BRAF, RAS, RET/PTC, and PAX8/PPARg alterations in different Bethesda diagnostic categories: A multicentric prospective study on the validity of the 7-gene panel test in 1172 thyroid FNAs deriving from different hospitals in South ItalyClaudio Bellevicine, Ilaria Migliatico, Roberta Sgariglia, et al.
Archives of Disease in Childhood|January 14, 2019
Complications and risk factors for severe outcome in children with measlesAndrea Lo Vecchio, Andrzej Krzysztofiak, Carlotta Montagnani, et al.
Leukemia Research|June 3, 2026
Association of hypomethylating agents + venetoclax in the real-life treatment of Myeloproliferative Neoplasms in blastic phaseRoberto Latagliata, Novella Pugliese, Dorela Lame, et al.
Annals of Hematology|January 11, 2026
Hypomethylating agents alone or in combination with venetoclax in very elderly acute myeloid leukemia patients: less treatment, better care?Francesco Tarantini, Corinne Contento, Ernesto Vigna, et al.
Hematological Oncology|May 31, 2022
Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trialsEnrica Antonia Martino, Concetta Conticello, Elena Zamagni, et al.
Clinical Rheumatology|July 7, 2022
Apremilast retention rate in clinical practice: observations from an Italian multi-center studyAlarico Ariani, Simone Parisi, Patrizia Del Medico, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|November 3, 2022
Booster dose of SARS-CoV-2 messenger RNA vaccines strengthens the specific immune response of patients with rheumatoid arthritis: A prospective multicenter longitudinal studyChiara Farroni, Alessandra Aiello, Andrea Picchianti-Diamanti, et al.
Current Oncology (Toronto, Ont.)|February 26, 2026
BLOSSOM Dietary Habits and 1-Year Intravesical Recurrence in High-Risk Non-Muscle-Invasive Bladder Cancer Treated with BCGCarlo Buonerba, Raffaele Baio, Felice Crocetto, et al.
Cancer Discovery|April 19, 2026
TNG961 is a selective oral HBS1L molecular glue degrader for the treatment of FOCAD-deleted cancersHilary E Nicholson, Douglas A Whittington, Frank J Bruzzese, et al.
Molecular Cell|February 5, 2010
Substrate-assisted inhibition of ubiquitin-like protein-activating enzymes: the NEDD8 E1 inhibitor MLN4924 forms a NEDD8-AMP mimetic in situJames E Brownell, Michael D Sintchak, James M Gavin, et al.
Pageof 77